^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Norepinephrine reuptake inhibitor

    Related drugs:
    3d
    Analgesic Equivalence of NSAIDs and Tramadol in Acute Postoperative Pain Following Minimally Invasive Surgery (clinicaltrials.gov)
    P=N/A, N=30, Completed, ISSSTE Hospital Regional "Gral. Ignacio Zaragoza" | Initiation date: Jan 2024 --> Jun 2024
    Trial initiation date
    3d
    A Study of CSTI-500 in Patients With Prader-Willi Syndrome (clinicaltrials.gov)
    P2, N=12, Recruiting, ConSynance Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    4d
    Buprenorphine vs tapentadol for pain management post haemorrhoidectomy: an open-label randomised clinical trial (BOLT) (ACTRN12626000598381)
    P=N/A, N=52, Not yet recruiting, Prince of Wales Hospital
    New trial
    4d
    Dexmedetomidine vs Tramadol for Anxiety, Pain, and Hemodynamics in Hemorrhoidectomy (clinicaltrials.gov)
    P=N/A, N=90, Active, not recruiting, Yuzuncu Yil University | Recruiting --> Active, not recruiting
    Enrollment closed
    4d
    A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder. (clinicaltrials.gov)
    P3, N=680, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc. | Active, not recruiting --> Completed
    Trial completion
    5d
    A Phase 1, First-in-human Study of VX-433 (clinicaltrials.gov)
    P1, N=118, Not yet recruiting, Vertex Pharmaceuticals Incorporated
    New P1 trial • First-in-human
    |
    midazolam hydrochloride
    6d
    Solriamfetol and CBT-I in Patients With Insomnia Disorder (clinicaltrials.gov)
    P4, N=115, Completed, University of Pennsylvania | Active, not recruiting --> Completed | N=60 --> 115
    Trial completion • Enrollment change
    11d
    P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety (clinicaltrials.gov)
    P3, N=315, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc. | Active, not recruiting --> Completed
    Trial completion
    12d
    PDC-1421 Treatment in Adult Patients With ADHD (clinicaltrials.gov)
    P2, N=99, Completed, BioLite, Inc. | N=70 --> 99
    Enrollment change
    12d
    BUPRO-05-25: An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover, bioavailability study comparing Bupropion Hydrochloride Extended Release Capsules 150 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with WELLBUTRIN XL (Bupropion hydrochloride) extended release tablets 300 mg, Distributed by: Bausch Health US, LLC Bridgewater, NJ 08807 USA. Manufactured by: Bausch Health Companies, Inc. Steinbach, MB R5G 1Z7, Canada, in healthy, adult, human subjects under fasting condition. (2025-523410-84-00)
    P1, N=72, Not yet recruiting, Sun Pharmaceutical Industries Limited
    New P1 trial
    12d
    BUPRO-06-25: An open label, balanced, randomized, three treatment, three period, three sequence, single dose, crossover study to assess the effect of food and effect of apple sauce on bioavailability of the Test nproduct (Bupropion Hydrochloride Extended Release Capsules 150 mg, manufactured by Sun Pharmaceutical Industries Limited, India) in healthy, adult, human subjects. (2025-523411-11-00)
    P1, N=72, Not yet recruiting, Sun Pharmaceutical Industries Limited
    New P1 trial
    12d
    Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 (clinicaltrials.gov)
    P3, N=45, Suspended, Cingulate Therapeutics | Trial completion date: Mar 2026 --> Feb 2027 | Trial primary completion date: Mar 2026 --> Feb 2027
    Trial completion date • Trial primary completion date